Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer
Autore:
Jillella, AP; Britt, GW; Litaker, MS; Kallab, AM; Harkness, K; Garner, GD;
Indirizzi:
Med Coll Georgia, Dept Med, Sect Hematol & Oncol, Augusta, GA 30912 USA Med Coll Georgia Augusta GA USA 30912 atol & Oncol, Augusta, GA 30912 USA
Titolo Testata:
MEDICAL ONCOLOGY
fascicolo: 4, volume: 17, anno: 2000,
pagine: 287 - 292
SICI:
1357-0560(200011)17:4<287:OAHCWC>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW SUPPORT; LONG-TERM SURVIVAL; OVARIAN-CANCER; HEARING-LOSS; PHASE-III; CISPLATIN; RESCUE; ETOPOSIDE; CHILDREN; LEUKEMIA;
Keywords:
breast cancer; autologous stem cell transplantation; ototoxicity; carboplatin; otoaccoustic emissions;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Jillella, AP Med Coll Georgia, Dept Med, Sect Hematol & Oncol, BAA 5407,1120 15th St, Augusta, GA 30912 USA Med Coll Georgia BAA 5407,1120 15th St Augusta GA USA 30912 A
Citazione:
A.P. Jillella et al., "Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer", MED ONCOL, 17(4), 2000, pp. 287-292

Abstract

Our purpose was to determine the risk of ototoxicity in breast cancer patients receiving a myeloablative regimen consisting of cyclophosphamide 6000 mg/m(2), thiotepa 500 mg/m(2) and carboplatin 800 mg/m(2) (CTCb) followed by stem cell transplantation. Fourteen consecutive patients with breast cancer were treated with high dose chemotherapy consisting of the CTCb regimen followed by stem cell transplantation. A pretransplant complete hearing study was obtained which consisted of hearing case history, audiometry and tympanometry. In addition, DPOAE (Distortion Product Otoaccoustic Emissions) was done to evaluate measurable changes in the cochlear (outer hair cell) functioning. Pre-transplant, all patients had no clinical evidence of hearing impairment and hearing studies were normal. Eleven patients had hearing studies and a telephone interview posttransplant. One patient was lost to follow-up andtwo patients died. One of the 11 patients tested had an abnormal post-transplant hearing study but none of them had clinically detectable hearing impairment. In our prospective study of breast cancer patients treated with the CTCb regimen, we did not observe clinically detectable hearing impairment in any of the patients tested.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 19:49:45